Inhibitory Action of α-Difluoromethylornithine on N-Butyl-N-(4-hydroxybutyl)nitrosamine-induced Rat Urinary Bladder Carcinogenesis

Katsunori Uchida, Ryoichi Oyasu, Jerome Seidenfeld, Alfred Rademaker

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

We previously have shown that urine components capable of stimulating ornithine decarboxylase activity of urot helium can enhance rat urinary bladder carcinogenesis, and that a-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase, suppresses carcinogen-initiated rat urinary bladder carcinogenesis. The present investigation was conducted to determine whether DFMO's suppressive effect is stage specific during carcinogenesis and whether the suppressive effect lasts with its continued use. Following initiation with 0.05% N-butyl-N-(4-hydroxybutyl)-nitrosamine in drinking water for 6 wk, male Fischer 344 rats initially weighing 125 to 150 g were randomly divided into two groups, the first receiving 0.2% DFMO in drinking water ad libitum and the second receiving tap water only. Groups of animals were killed at regular intervals until the completion of the experiment at 75 wk. The effect of DFMO was evaluated by monitoring the incidence of tumors, the mean number of tumors per rat, the mean volume of individual tumors, and the mean total tumor volume per rat. The results showed that continuous treatment with DFMO significantly reduced tumor formation until 60 wk (P < 0.017). The effect was only of borderline significance (0.017 < P < 0.035) at 75 wk. Discontinuation of DFMO treatment at 40 wk resulted in the loss of protective effect in all comparisons except for the borderline effect on the tumor number and total tumor volume per rat. DFMO had no significant effect on the incidence or development of preneoplastic early lesions. Mucosal polyamine (spermidine and sperimine) levels were reduced and correlated well with the reduction in tumor growth, suggesting that the reduction in tumor growth rate by DFMO may be due to its ability to reduce polyamine levels in urothelium. There were no side effects attributable to DFMO treatment. DFMO may be a useful chem-opreventive agent to retard the recurrence of human superficial bladder cancer.

Original languageEnglish (US)
Pages (from-to)5249-5253
Number of pages5
JournalCancer Research
Volume49
Issue number19
StatePublished - Oct 15 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Inhibitory Action of α-Difluoromethylornithine on N-Butyl-N-(4-hydroxybutyl)nitrosamine-induced Rat Urinary Bladder Carcinogenesis'. Together they form a unique fingerprint.

Cite this